Dataset Information

Mesenchymal stem cells negatively regulate CD4⁺ T cell activation in patients with primary Sjögren syndrome through the miRNA‑125b and miRNA‑155 TCR pathway.

ABSTRACT: Treatment with mesenchymal stem cells (MSCs) has been revealed to suppress CD4⁺ T cells and autoimmunity in both mouse models and patients with primary Sjögren syndrome (pSS); however, the underlying mechanism remains unclear. MicroRNAs (miRNAs or miRs) mediate CD4⁺ T cell activation, but the mechanism is not understood, particularly for CD4⁺ T cells treated with MSCs. Characterization of miRNAs may reveal pSS pathogenesis, guide MSC treatment and provide more personalized management options. The present study aimed to perform an miRNome analysis of quiescent and T cell receptor (TCR)‑activated CD4⁺ T cells treated with MSCs via miRNA proﬁles and bioinformatics. Following 72 h of co‑culture, MSCs inhibited TCR‑induced CD4⁺ T cell activ

SUBMITTER: Gong B

PROVIDER: S-EPMC7684863 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Mesenchymal stem cells negatively regulate CD4⁺ T cell activation in patients with primary Sjögren syndrome through the miRNA‑125b and miRNA‑155 TCR pathway.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Mesenchymal stem cells negatively regulate CD4+ T cell activation in patients with primary Sjögren syndrome through the miRNA‑125b and miRNA‑155 TCR pathway.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Mesenchymal stem cells negatively regulate CD4⁺ T cell activation in patients with primary Sjögren syndrome through the miRNA‑125b and miRNA‑155 TCR pathway.